Differential chemotherapeutic sensitivity for breast tumors with "BRCAness":A review

Oncologist

Volumn 18, Issue 8, 2013, Pages 909-916

  Chalasani, Pavani ^a   Livingston, Robert ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

BRCA mutations; BRCAness; Breast cancer; Differential chemosensitivity

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; HORMONE RECEPTOR; INIPARIB; MESSENGER RNA; METHOTREXATE; OLAPARIB; PACLITAXEL; PREDNISONE; THIOTEPA; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CHEMOSENSITIVITY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM;

BRCA MUTATIONS; BRCANESS; BREAST CANCER; DIFFERENTIAL CHEMOSENSITIVITY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; GENOMIC INSTABILITY; GENOTYPE; HOMOLOGOUS RECOMBINATION; HUMANS; MUTATION;

EID: 84883245810     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0039     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-2347.
3. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819.
4. Turner N, Tutt A, Ashworth A. Targeting the DNArepair defect of BRCAtumours. Curr Opin Pharmacol 2005;5:388-393.
5. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001;114:3591-3598.
6. Collins N, McManus R, Wooster R et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-1675.
7. Cornelis RS, Neuhausen SL, Johansson O et al. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 1995;13:203-210.
8. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
9. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet 1998;32:95-121.
10. Rhiem K, Todt U, Wappenschmidt B et al. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Res 2010;30: 3445-3449.
11. Catteau A, Harris WH, Xu CF et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. Oncogene 1999;18:1957-1965.
12. Grushko TA, Dignam JJ, Das S et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004;10:499-507.
13. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482-1485.
14. Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-5180.
15. Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 2002;20:2310-2318.
16. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1Cp Gisland promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998;17:1807-1812.
17. Rice JC, Ozcelik H, Maxeiner P et al. Methylation of the BRCA1 promoter is associated with decreased BRCA1mRNAlevels in clinical breast cancer specimens. Carcinogenesis 2000;21:1761-1765.
18. Lips EH, Mulder L, Hannemann J et al. Indicators of homologous recombination deficiency in breast cancerandassociation with response to neoadjuvant chemotherapy. Ann Oncol 2011;22:870-876.
19. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-569.
20. Staff S, Isola J, Tanner M. Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res 2003;63:4978-4983.
21. Bosviel R, Durif J, Guo J et al. BRCA2 promoter hypermethylation in sporadic breast cancer. OMICS 2012;16:707-710.
22. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-535.
23. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
24. Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-6228.
25. De Ligio JT, Velkova A, Zorio DA et al. Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem 2009;9:543-549.
26. Rottenberg S, Nygren AO, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007;104:12117-12122.
27. Mullan PB, Quinn JE, Gilmore PM et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001; 20:6123-6131.
28. Lafarge S, Sylvain V, Ferrara M et al. Inhibition of BRCA1leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20:6597-6606.
29. Chabalier C, Lamare C, Racca C et al. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006;5:1001-1007.
30. Gilmore PM, McCabe N, Quinn JE et al. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res 2004;64:4148-4154.
31. Kriege M, Jager A, Hooning MJ et al. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012;118:899-907.
32. Kriege M, Seynaeve C, Meijers-Heijboer H et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27:3764-3771.
33. Gronwald J, Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients [abstract 502]. J Clin Oncol 2009; 27(suppl):15s.
34. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009;115:359-363.
35. Byrski T, Dent R, Blecharz P et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012; 14:R110.
36. Byrski T, Gronwald J, Huzarski T et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008;108:289-296.
37. Vollebergh MA, Lips EH, Nederlof PM et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinumbased chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22:1561-1570.
38. Egawa C, Motomura K, Miyoshi Y et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003;78:45-50.
39. Sharma P, Kimler BF, Park YA et al. Association of BRCA1 promoter methylation in triple-negative breast cancer (TNBC) with resistance to standard anthracycline-based adjuvant chemotherapy. J Clin Oncol 2011;29(suppl):abstract 1123.
40. Sharma P, Stecklein S, Kimler BF et al. BRCA1 insufficiency is predictive of superior survival in patients with triple negative breast cancer treated with platinum based chemotherapy. Cancer Res 2012;72(suppl):abstract PD09-02.
41. Kurebayashi J, Yamamoto Y, Kurosumi M et al. Loss of BRCA1expressionmaypredictshortertime-toprogression in metastatic breast cancer patients treated with taxanes. Anticancer Res 2006;26:695-701.
42. Rodriguez AA, Makris A, Wu MF et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010;123:189-196.
43. Egawa C, Miyoshi Y, Takamura Y et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001;95:255-259.
44. Alli E, Sharma VB, Sunderesakumar P et al. Defective repair of oxidative dnadamagein triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009; 69:3589-3596.
45. Iglehart JD, Silver DP. Synthetic lethality-new direction in cancer-drug development. NEngl JMed 2009;361:189-191.
46. Tutt A, Robson M, Garber JE et al. Oral poly-(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376:235-244.
47. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib pluschemotherapyinmetastatictriple-negative breast cancer. N Engl JMed 2011;364:205-214.
48. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29(suppl):abstract 1007.
49. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-861.
50. Telli ML, Jensen KC, Abkevich V et al. Homologousre combination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC). Cancer Res 2012;72(suppl):abstract PD09-04.
51. Jiuping J, Lee MP, Kadota M et al. Pharmacodynamic and pathway analysis of three presumed inhibitorsofpoly(ADP-ribose)polymerase:ABT-888, AZD2281 and BSI201. Cancer Res 2011;71(suppl):abstract4527.
52. Chionh F, Mitchell G, Lindeman GJ et al. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. Asia Pac J Clin Oncol 2011;7:197-211.
53. Delaloge S, Pelissier P, Kloos I et al. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Paper presented at: 27th Congress of the European Society of Medical Oncology.
54. Chappuis PO, Goffin J, Wong N et al. Asignificantresponse to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608-610.
55. Byrski T, Gronwald J, Huzarski T et al. Pathologiccompleteresponse rates inyoungwomenwith BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-379.
56. Isakoff SJ, Goss PE, Mayer EL et al. Impact of BRCA1/2 mutation status in TBCRC009: A muticenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. Cancer Res 2012;72(suppl):abstract PD09-03.
57. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-1153.
58. Oonk AM, van Rijn C, Smits MM et al. Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol 2012;23:2301-2305.